• SENSEX 82,104.79
    512.34 (+0.63%)
  • BANKNIFTY 61,575.90
    541.80 (+0.89%)
Back

Results - Announcements

Transgene Biotek Ltd share price gained 3.53% to Rs 2.64

Transgene Biotek Ltd consolidated sales down remained flat on year in Q2FY2027
16-Nov-2026, 07:47

Transgene Biotek Ltd's net loss stood at Rs 0.35 crore in Q2FY2027 compared to a net loss of Rs 0.39 crore in Q2FY26. The revenue from operations remained flat to Rs 0.06 crore in Q2FY27 over Q2FY26.


The market capitalization of Healthcare Service Provider industry group stocks on BSE stood at Rs 83415.97 crore, improving 10.04%. It has marginally improved by 0.47% over last one week and dipped slightly by 0.23% in last one month while the market capitalization of Transgene Biotek Ltd has softened by 3.14% and 14.36% in the same period respectively.


Profit before tax (PBT) of Transgene Biotek Ltd stood at Rs 0.35 crore in Q2 FY27, falling 10.26% year-on-year, and retreating 10.26% quarter-on-quarter. EBITDA came in at Rs 0 crore, crashing by 71.43% YoY and tumbling by 66.67% sequentially.


Total expenses saw a steep drop of 25% to Rs 0.12 crore in Q2FY27 over Q2FY26. During the quarter, employee benefits expense was at Rs 0.03 crore, remaining flat YoY.


For FY26, revenue from operations advanced 13.04% to Rs 0.26 crore, while net profit grew slightly 3.03% to Rs 0.68 crore, compared to previous FY. EBITDA tanked by 180% to Rs 1.91 crore, and PBT inched up 3.03% to Rs 0.68 crore compared to previous FY.


Transgene Biotek Ltd nosedived by 32.31% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.42% during the same period.